ClinicalTrials.gg
RecruitingNCT07275918Updated Dec 10, 2025

SA1211 Injection Phase 1 Study

A Phase 1 interventional study of SA1211 injection and SA1211 injection placebo in Chronic Hepatitis B, sponsored by Suzhou Siran Biotechnology Co.,Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Suzhou Siran Biotechnology Co.,Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 378 studies in Hepatitis B, Chronic with a site in China — 91 open to participants now, 112 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
190th of 274
80 · median 120
Started
2025
with 23 others
Phase 1
51 of 378
17 open now
Primary completion
2027-03
later than 58 of 111 live
Registered
340th of 378
by date

Among the 378 studies in Hepatitis B, Chronic with a site in China, this one is the 190th largest by planned enrollment of the 274 interventional ones that give a count, is one of 24 that started in 2025, is one of 51 in phase 1, reaches primary completion later than 58 of the 111 other live ones, and was the 340th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

91 of the 378 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

85 more — sign in →

All 91 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 378 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of SA1211 Injection in healthy volunteers (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in participants with chronic hepatitis B (CHB). The main questions it aims to answer are:

What are the safety, tolerability, immunogenicity and PK characteristics of a single subcutaneous injection of SA1211 Injection in healthy volunteers (Part A)? What are the safety, tolerability, immunogenicity and PK characteristics of multiple subcutaneous injections of SA1211 Injection in participants with CHB (Part B)? What is the preliminary efficacy of SA1211 Injection in participants with CHB (Part B)?

Participants will:

  • Part A (healthy volunteers): Receive a single subcutaneous injection of SA1211 Injection or placebo and complete relevant safety, tolerability and PK monitoring as required.
  • Part B (participants with CHB): Receive multiple subcutaneous injections of SA1211 Injection or placebo and complete relevant safety, tolerability, PK monitoring and preliminary efficacy assessment as required.
03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • CHB
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to correctly understand and sign the form in writing.
  2. Male or female participants.

    • For healthy participants: aged 18-55 years old (inclusive of the cut-off values).
    • For participants with chronic (CHB): aged 18-65 years old (inclusive of the cut-off values).
  3. (BMI) meets the following requirements.

    • For healthy participants: within the range of 18-28 kg/m² (inclusive of the cut-off values).
    • For participants with chronic hepatitis B (CHB): within the range of 18-32 kg/m² (inclusive of the cut-off values).
  4. During the screening period, the results of the following examinations are either normal or abnormal but not clinically insignificant:

    - Clinical laboratory tests: complete blood count, blood biochemistry, coagulation function, urine routine. Thyroid function test. 12-lead (ECG). Abdominal ultrasound. Posteroanterior chest X-ray.

  5. For participants with chronic hepatitis B (CHB): documented hepatitis B virus (HBV) infection for at least 6 months before screening, with positive hepatitis B surface antigen (HBsAg) and/or positive HBV deoxyribonucleic acid (HBV DNA).
  6. For female participants of : must not be pregnant or lactating, and agree to use effective during the study period.
  7. For male participants of childbearing potential: agree to use effective contraception during the study period to ensure effective contraception for their sexual partners.

Exclusion criteria

Exclusion Criteria:

  1. Participants with concurrent virus (HCV), (HIV) or syphilis infection; or those previously diagnosed with hepatitis A, D, or E who have not been cured.
  2. Participants with severe diseases, including but not limited to diseases of the nervous, cardiovascular, hematological and lymphatic, immune, renal, hepatic, thyroid, gastrointestinal, respiratory, metabolic, and skeletal systems, as well as a history of malignant tumors.
  3. Participants with severe mental illness or uncontrolled mental disorders, including but not limited to schizophrenia, bipolar disorder, or depression.
  4. Participants with a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at screening, who are deemed unsuitable for the study by the investigator.
  5. Participants who have undergone major surgery within 6 months before screening, or plan to undergo surgery during the study period.
  6. Participants with severe infection or trauma within 4 weeks before screening.
  7. Participants with a severe allergic constitution, or a confirmed allergy to this product or its formulation components.
  8. Participants who smoked more than 5 cigarettes per day or the equivalent amount of tobacco within 3 months before screening.
  9. Participants deemed unsuitable for the trial by the investigator due to other factors.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Healthy Participants

    Drug: SA1211 injection · Drug: SA1211 injection placebo

  • Experimental
    Chronic Hepatitis B

    Drug: SA1211 injection · Drug: SA1211 injection placebo

Interventions

  • DrugSA1211 injection

    subcutaneous injection

  • DrugSA1211 injection placebo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of participants with AEs, SAEs and abnormal laboratory testings

    AEs: Adverse Events. SAEs: Serious Adverse Events.

    Time frame: Approximate 24 weeks

Secondary outcomes

  1. Cmax: maximum concentration

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  2. Tmax

    Tmax: Time to Maximum Concentration

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  3. AUC0-t

    AUC0-t: Area Under the Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  4. AUC0-inf

    AUC0-inf: Area Under the Concentration-Time Curve from Time Zero to Infinity

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  5. t1/2

    t1/2: Half-life

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  6. λz

    λz: Terminal Elimination Rate Constant

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  7. Vd/F

    Vd/F: Volume of Distribution over Bioavailability

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  8. CL/F

    CL/F: Clearance over Bioavailability

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  9. Css (Steady-State Concentration)

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  10. DF (Degree of Fluctuation)

    Time frame: Pre-dose, multiple time-points post dose until 48 hours

  11. The number of participants with chronic hepatitis B (CHB) who achieved hepatitis B surface antigen (HBsAg) clearance

    Time frame: Approximate 24 weeks

  12. Maximum HBsAg Decline in CHB Participants Within 24 Weeks (log10)

    Time frame: Approximate 24 weeks

  13. The number of CHB Participants with HBsAg Seroconversion at each assessment time Point within 24 weeks

    Time frame: Approximate 24 weeks

  14. The number of CHB participants who achieved HBeAg seronegativity at each assessment time point within 24 weeks

    Time frame: Approximate 24 weeks

  15. The number of participants with immunogenicity (i.e., anti-drug antibodies [ADAs])

    Time frame: Approximate 24 weeks

  16. The change in QTcF relative to baseline and the change relative to placebo

    Apply for healthy participants

    Time frame: Approximate 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.

Of 74 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 16 months is close to that.

Counting every sponsor, half of 82 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 10, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2027
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275918
Lead sponsor
Suzhou Siran Biotechnology Co.,Ltd.
Collaborators
Beijing Siran Biotechnology Co.,Ltd.
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Nov 25, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Dec 10, 2025

Study contacts

Feifei Zhao
Contact
zhaofeifei@siranbio.com
+86 0512-65295926

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion